Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Alnylam Pharma, with a price target of $425.00.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Nakae is a 4-star analyst with an average return of 4.6% and a 39.60% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and Reviva Pharmaceuticals Holdings.

In addition to Chardan Capital, Alnylam Pharma also received a Buy from TD Cowen’s Ritu Baral in a report issued today. However, on February 3, TipRanks – Google reiterated a Hold rating on Alnylam Pharma (NASDAQ: ALNY).

Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.25 billion and a net profit of $251.08 million. In comparison, last year the company earned a revenue of $500.92 million and had a GAAP net loss of $111.57 million

Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year. Last month, Jeffrey V. Poulton, the EVP & CFO of ALNY sold 2,780.00 shares for a total of $1,008,765.87.